Role of angiotensin II in glomerular injury.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Seminars in Nephrology

• Publication date

  2001-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1053/SNEP.2001.26793PMID 11709802
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Balance between matrix synthesis and degradation: a determinant of glomerulosclerosis

  2004cited by this paper
• Progression and potential regression of glomerulosclerosis.

  2001cited by this paper
• Angiotensin II type 1 receptor gene polymorphisms in humans: physiology and pathophysiology of the genotypes

  2001cited by this paper
• Aldosterone in renal disease.

  2001cited by this paper
• Glomerular hypertension, abnormal glomerular growth, and progression of renal diseases.

  2000cited by this paper
• Gene transfer of endothelial nitric oxide synthase reduces angiotensin II-induced endothelial dysfunction.

  2000cited by this paper
• Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo.

  2000cited by this paper
• Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo.

  2000cited by this paper
• Regression of sclerosis in aging by an angiotensin inhibition-induced decrease in PAI-1.

  2000cited by this paper
• Angiotensin II type 1 receptor gene polymorphism and the response to hyperglycemia in early type 1 diabetes.

  2000cited by this paper
• AT(1) and AT(2) receptors in the kidney: role in disease and treatment.

  2000cited by this paper
• The role of angiotensin II and plasminogen activator inhibitor-1 in progressive glomerulosclerosis.

  2000cited by this paper
• Blood pressure-independent effects in rats with human renin and angiotensinogen genes.

  2000cited by this paper
• NF-κB Inhibition Ameliorates Angiotensin II–Induced Inflammatory Damage in Rats

  2000cited by this paper
• Effect of beta(2)-adrenoceptor activation and angiotensin II on tumour necrosis factor and interleukin 6 gene transcription in the rat renal resident macrophage cells.

  1999cited by this paper
• Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans.

  1999cited by this paper
• Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway.

  1999cited by this paper
• Expansion of cortical interstitium is limited by converting enzyme inhibition in type 2 diabetic patients with glomerulosclerosis. The Diabiopsies Group.

  1999cited by this paper
• Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy.

  1999cited by this paper
• Angiotensin II type 2 receptor blockade amplifies the early signals of cardiac growth response to angiotensin II in hypertrophied hearts.

  1999cited by this paper
• Localization of angiotensin AT1 and AT2 receptors.

  1999cited by this paper
• Angiotensin II plays a pathogenic role in immune-mediated renal injury in mice.

  1999cited by this paper
• Protective role of the angiotensin AT2 receptor in a renal wrap hypertension model.

  1999cited by this paper
• Angiotensin converting-enzyme inhibitor treatment reduces glomerular p16INK4 and p27Kip1 expression in diabetic BBdp rats

  1999cited by this paper
• The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2000 by The Endocrine Society Synergistic Effect of Adrenal Steroids and Angiotensin II on Plasminogen Activator Inhibitor-1 Production*

  1999cited by this paper
• Angiotensin II receptors.

  1999cited by this paper
• Bradykinin stimulates tissue plasminogen activator release in human vasculature.

  1999cited by this paper
• Angiotensin II type 1 receptor gene polymorphism predicts response to losartan and angiotensin II.

  1999cited by this paper
• Mesangial Matrix Modulation and Glomerulosclerosis

  1999cited by this paper
• New insights into the renin-angiotensin system and hypertensive renal disease

  1999cited by this paper
• Losartan-sensitive renal damage caused by chronic NOS inhibition does not involve increased renal angiotensin II concentrations.

  1999cited by this paper
• Renal arterioles in patients with type I diabetes and microalbuminuria before and after treatment with antihypertensive drugs

  1999cited by this paper
• Combination ACE Inhibitor and Angiotensin II Receptor Antagonist Therapy in Diabetic Nephropathy

  1999cited by this paper
• Angiotensin-converting enzyme inhibitors.

  1998cited by this paper
• Additive effects of enalapril and losartan in (mREN-2)27 transgenic rats.

  1998cited by this paper
• Serial Alterations of Glomerular Matrix-Degrading Metalloproteinase Activity in Anti-Thymocyte-Induced Glomerulonephritis in Rats

  1998cited by this paper
• Characterization and purification of the bovine adrenal angiotensin IV receptor (AT4) using [125I]benzoylphenylalanine-angiotensin IV as a specific photolabel.

  1998cited by this paper
• Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation.

  1998cited by this paper
• Reversal of lesions of diabetic nephropathy after pancreas transplantation.

  1998cited by this paper
• Documentation of angiotensin II receptors in glomerular epithelial cells.

  1998cited by this paper
• Accelerated fibrosis and collagen deposition develop in the renal interstitium of angiotensin type 2 receptor null mutant mice during ureteral obstruction.

  1998cited by this paper
• The antithrombotic effect of captopril and losartan on experimental arterial thrombosis in rats.

  1998cited by this paper
• Autoradiographic identification of kidney angiotensin IV binding sites and angiotensin IV-induced renal cortical blood flow changes in rats.

  1998cited by this paper
• Angiotensin IV AT4-receptor system in the rat kidney.

  1998cited by this paper
• Angiotensin converting enzyme gene I/D polymorphism in essential hypertension and nephroangiosclerosis.

  1998cited by this paper
• Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats.

  1998cited by this paper
• Polymorphisms of angiotensin converting enzyme and plasminogen activator inhibitor-1 genes in diabetes and macroangiopathy1.

  1998cited by this paper
• Dual effects of angiotensin II on the plasminogen/plasmin system in rat mesangial cells.

  1997cited by this paper
• Angiotensin type 2 receptors are reexpressed by cardiac fibroblasts from failing myopathic hamster hearts and inhibit cell growth and fibrillar collagen metabolism.

  1997cited by this paper
• Angiotensin-converting enzyme gene polymorphism in patients with minimal-change nephrotic syndrome and focal segmental glomerulosclerosis.

  1997cited by this paper
• Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators.

  1997cited by this paper
• Angiotensin receptor antagonists in experimental models of chronic renal failure.

  1997cited by this paper
• Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition.

  1997cited by this paper
• Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes: Genetique de la Nephropathie Diabetique (GENEDIAB) study group.

  1997cited by this paper
• Should hyperlipidaemia in dialysis patients be treated?

  1997cited by this paper
• Losartan reduces albuminuria in patients with essential hypertension. An enalapril controlled 3 months study.

  1997cited by this paper
• Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats.

  1997cited by this paper
• Angiotensin-independent mechanism for aldosterone synthesis during chronic extracellular fluid volume depletion.

  1997cited by this paper
• Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography.

  1997cited by this paper
• Angiotensin I converting enzyme gene polymorphism in non-insulin dependent diabetes mellitus.

  1996cited by this paper
• Angiotensin II type 2 receptor mediates programmed cell death.

  1996cited by this paper
• Role of aldosterone in the remnant kidney model in the rat.

  1996cited by this paper
• Specific receptor binding of renin on human mesangial cells in culture increases plasminogen activator inhibitor-1 antigen.

  1996cited by this paper
• Angiotensin converting enzyme gene polymorphism: potential silencer motif and impact on progression in IgA nephropathy.

  1996cited by this paper
• The Renin-Angiotensin and fibrinolytic systems co-conspirators in the pathogenesis of ischemic cardiovascular disease.

  1996cited by this paper
• Angiotensin II receptor antagonist ameliorates renal tubulointerstitial fibrosis caused by unilateral ureteral obstruction.

  1995cited by this paper
• Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV.

  1995cited by this paper
• The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer.

  1995cited by this paper
• Role of the deletion of polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy.

  1995cited by this paper
• ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade.

  1995cited by this paper
• Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor

  1995cited by this paper
• Balance between matrix synthesis and degradation: a determinant of glomerulosclerosis

  1995cited by this paper
• Angiotensin converting enzyme genotypes and disease

  1995cited by this paper
• Angiotensin converting enzyme inhibitor modulates glomerular function and structure by distinct mechanisms.

  1994cited by this paper
• Inhibitors of angiotensin converting enzyme decrease early atherosclerosis in hyperlipidemic hamsters. Fosinopril reduces plasma cholesterol and captopril inhibits macrophage-foam cell accumulation independently of blood pressure and plasma lipids.

  1994cited by this paper
• The emerging role of transforming growth factor-beta in kidney diseases.

  1994cited by this paper
• Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition.

  1993cited by this paper
• Stimulation of Plasminogen Activator Inhibitor In Vivo by Infusion of Angiotensin II Evidence of a Potential Interaction Between the Renin‐Angiotensin System and Fibrinolytic Function

  1993cited by this paper
• Differential effects of renin-angiotensin system blockade on atherogenesis in cholesterol-fed rabbits.

  1993cited by this paper
• Angiotensin II stimulates the proliferation and biosynthesis of type I collagen in cultured murine mesangial cells.

  1992cited by this paper
• Renal protective effect of angiotensin-converting enzyme inhibition in aging rats.

  1992cited by this paper
• Proteinases and glomerular matrix turnover.

  1992cited by this paper
• Renal injury from angiotensin II-mediated hypertension.

  1992cited by this paper
• The plasminogen activator/plasmin system.

  1991cited by this paper
• Cause of variable therapeutic efficiency of angiotensin converting enzyme inhibitor on glomerular lesions.

  1991cited by this paper
• Enalapril and low protein reverse chronic puromycin aminonucleoside nephropathy.

  1990cited by this paper
• Glomerular hypertrophy in minimal change disease predicts subsequent progression to focal glomerular sclerosis.

  1990cited by this paper
• Effects of antihypertensive drugs on glomerular morphology.

  1989cited by this paper
• Glomerular hemodynamic changes vs. hypertrophy in experimental glomerular sclerosis.

  1989cited by this paper
• Serial micropuncture analysis of glomerular function in two rat models of glomerular sclerosis.

  1988cited by this paper
• Reversal of Mesangial Enlargement in Rats With Long-standing Diabetes by Whole Pancreas Transplantation

  1986cited by this paper
• Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass.

  1985cited by this paper
• Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease.

  1982cited by this paper
• Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation.

  1981cited by this paper
• Downloaded from http://hyper.ahajournals.org / by guest on February 21, 2013Role of Aldosterone in Renal Vascular Injury in Stroke-Prone Hypertensive Rats

  year unknowncited by this paper

• Relation of ACE2 with co-morbidity factors in SARS-CoV-2 pathogenicity

  2023cites this paper
• TRP Channels in Renal Epithelia

  2020cites this paper
• Long-Term Effects of Spironolactone on Kidney Function and Hyperkalemia-Associated Hospitalization in Patients with Chronic Kidney Disease

  2018cites this paper
• Lisinopril versus lisinopril and losartan for mild childhood IgA nephropathy: a randomized controlled trial (JSKDC01 study)

  2018cites this paper
• Renin Angiotensin System and Cytokines in Chronic Kidney Disease: Clinical and Experimental Evidence.

  2017cites this paper
• Melatonin protects podocytes from angiotensin II-induced injury in an in vitro diabetic nephropathy model.

  2016cites this paper
• Intrarenal angiotensin II plays an important role in renal fibrosis in primary IgA nephropathy.

  2016cites this paper
• Role of renal TRP channels in physiology and pathology

  2015cites this paper
• Pentoxifylline (PTF) and Kidney

  2015cites this paper
• The inhibitory effect of angiotensin II on BKCa channels in podocytes via oxidative stress

  2014cites this paper
• Insulin treatment attenuates renal ADAM17 and ACE2 shedding in diabetic Akita mice.

  2014cites this paper
• Mechanisms of disease reversal in focal and segmental glomerulosclerosis.

  2014cites this paper
• Mechanisms of Disease Reversal in FSGS

  2014cites this paper
• Renin-Angiotensin System (Part II) Dual Blockade of the -- Review: Preventing End-Stage Renal Disease in Diabetic Patients

  2013cites this paper
• Insulin Treatment Att enuates Renal ADAM17 and ACE2 Shedding in Akita Diabetic Mice

  2013cites this paper
• Angiotensin II induces tumor necrosis factor-α expression and release from cultured human podocytes

  2012cites this paper
• Influence of a novel inhibitor (UM8190) of prolylcarboxypeptidase (PRCP) on appetite and thrombosis.

  2012cites this paper
• Pirfenidone for diabetic nephropathy.

  2011cites this paper
• Effects of Angiotensin Receptor Blocker on Phenotypic Alterations of Podocytes in Early Diabetic Nephropathy

  2011cites this paper
• Role of angiotensin II in the development of nephropathy and podocytopathy of diabetes.

  2011cites this paper
• Investigación de nuevas estrategias terapeúticas para la inflamación y la fibrosis hepática.

  2010cites this paper
• Albumin caused the increasing production of angiotensin II due to the dysregulation of ACE/ACE2 expression in HK2 cells.

  2009cites this paper
• Transforming growth factor-β and kidney dysfunction

  2009cites this paper
• PAI-1 and kidney fibrosis.

  2009cites this paper
• Cytokines and renin-angiotensin system signaling in hepatic fibrosis.

  2008cites this paper
• Urinary mRNA expression of ACE and ACE2 in human type 2 diabetic nephropathy

  2008cites this paper
• Renal effects of dual renin–angiotensin–aldosterone system blockade in patients with diabetic nephropathy

  2008cites this paper
• Angiotensin II activates plasminogen activator inhibitor-I promoter in renal tubular epithelial cells via the AT1 receptor.

  2007cites this paper
• Modulation of glomerulosclerosis

  2007cites this paper
• Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease.

  2006cites this paper
• Expression and Effect of Inhibition of Aminopeptidase-A during Nephrogenesis

  2006influential citation
• Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: implications for albuminuria in diabetes.

  2006cites this paper
• The renal antifibrotic effects of angiotensin-converting enzyme inhibition involve bradykinin B2 receptor activation in angiotensin II-dependent hypertension

  2006cites this paper
• The kidney and hypertension: over 70 years of research.

  2006cites this paper
• Differential Effects of Antihypertensive Drugs on Renal and Glomerular Hemodynamics and Injury in the Chronic Nitric-Oxide-Suppressed Rat

  2005cites this paper
• Review: Preventing End-Stage Renal Disease in Diabetic Patients — Dual Blockade of the Renin-Angiotensin System (Part II)

  2005cites this paper
• Regression of glomerulosclerosis with high-dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor-1.

  2005cites this paper
• AT-1 receptor antagonism modifies the mediation of endothelin-1, thromboxane A2, and catecholamines in the renal constrictor response to angiotensin II.

  2005cites this paper
• Combining laser capture microdissection and MALDI mass spectrometry for tissue protein profiling: methodology development and clinical applications

  2005cites this paper
• Proteomic patterns and prediction of glomerulosclerosis and its mechanisms.

  2005cites this paper
• Regression of existing glomerulosclerosis by inhibition of aldosterone.

  2005cites this paper
• Nephrotic syndrome in children.

  2005cites this paper
• Aldosterone Antagonism Ameliorates Proteinuria and Nephrosclerosis Independent of Glomerular Dynamics in L-NAME/SHR Model

  2004cites this paper
• Antifibrotic effect of the Chinese herbs, Astragalus mongholicus and Angelica sinensis, in a rat model of chronic puromycin aminonucleoside nephrosis.

  2004cites this paper
• Divergent effects of low versus high dose anti-TGF-beta antibody in puromycin aminonucleoside nephropathy in rats.

  2004cites this paper
• PROCESSES OF FIBROGENESIS IN GLOMERULAR NEPHROPATHIES

  2004cites this paper
• Transforming growth factor-beta-dependent and -independent pathways of induction of tubulointerstitial fibrosis in beta6(-/-) mice.

  2003cites this paper
• Role of bradykinin in renoprotective effects by angiotensin II type 1 receptor antagonist in salt-sensitive hypertension.

  2003cites this paper
• Renal fibrosis.

  2003cites this paper
• Inflammation and angiotensin II.

  2003cites this paper
• Transforming Growth Factor-β-Dependent and -Independent Pathways of Induction of Tubulointerstitial Fibrosis in β6−/− Mice

  2003cites this paper
• Model of robust induction of glomerulosclerosis in mice: importance of genetic background.

  2003cites this paper
• Novel insights into renal fibrosis

  2003cites this paper
• STAT proteins mediate angiotensin II-induced production of TIMP-1 in human proximal tubular epithelial cells.

  2003cites this paper
• Hyperfiltration and glomerulosclerosis.

  2003cites this paper
• Sodium sensitive sites in the gastrointestinal tract stimulate natriuresis

  2002cites this paper
• Role of endothelin-1 and thromboxane A2 in renal vasoconstriction induced by angiotensin II in diabetes and hypertension.

  2002cites this paper
• Protéases et antiprotéases dans la progression des lésions de l’insuffisance rénale chronique

  2002cites this paper